Treatment of thyroid cancer has not changed substantially for many years; however, few effective therapies are available for tumors that are metastatic or unable to take up radioiodine. The author of this Viewpoint, therefore, argues for the need to increase individual treatment efficacy through the introduction of novel targeted therapies.
